Clinical Trial Update: Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1 [Phase 3]

View source ↗

Summary

A Phase 3 trial of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurotrophic Keratopathy

Drugs mentioned

• RGN-259 ophthalmic solutions (RGN-259 ophthalmic solution)

Snippet

Sponsor: ReGenTree, LLC | Conditions: Neurotrophic Keratopathy | Phase 3 | Status: TERMINATED | Results posted: 2023-08-14